USFDA declines to approve this Hormone Disorder therapy

TD Cowen analyst Yaron Werber had raised concerns about the lack of clarity around USFDA's decision in a note on Friday.

137
Medicine red round tablets making sign of cross reject, refuse, decline, denied, No
Picture: Pixabay

Last Updated on December 31, 2023 by The Health Master

Bengaluru: Denmark-based Ascendis Pharma A/S said the US Food & Drug Administration (USFDA) had declined to approve its experimental therapy to treat adult patients with a hormone disorder called hypoparathyroidism, citing concerns related to manufacturing control of the drug and device combination.

The agency, however, did not express concerns about the clinical data submitted and did not seek fresh pre-clinical or late-stage trials in a so-called complete response letter, the company said.

Ascendis’ US-listed shares rose 12 per cent in premarket trade. The USFDA, early last month, had identified unspecified deficiencies in the company’s application for approval of the therapy, TransCon PTH.

TD Cowen analyst Yaron Werber had raised concerns about the lack of clarity around USFDA’s decision in a note on Friday.

He said a complete response letter declining approval was likely, adding the stock will slump if the USFDA sought another pre-clinical or clinical study as this would delay approval by 1.5-2 years.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news